Hanmi Science Co (008930.KS) Stock Price

Hanmi Science Co Price

🇰🇷KOSDAQ·CLOSED
30,750.00KRW
Market closed
Today +/-
Today %

Hanmi Science Co (008930.KS) Stock | ISIN KR7008930000. The current Hanmi Science Co stock price is 30,750 KRW (2026). Market capitalization is 2.08 T KRW. Hanmi Science Co operates in the Health sector.

Revenue has compounded at 6.4% per year over the past 19 years to 1.28 T KRW. Earnings per share have declined at 5% per year over the last 19 years. Hanmi Science Co's net margin stands at 4.6%, up from 2.6% several years earlier. Hanmi Science Co currently offers a dividend yield of about 0.98%. The payout ratio is around 28% of earnings.

Hanmi Science Co stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Hanmi Science Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hanmi Science Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hanmi Science Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Hanmi Science Co Stock Price History
DateHanmi Science Co Price
Access this data via the Eulerpool API

Hanmi Science Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
396.02 B KRW
58.99 B KRW
41.85 B KRW
Jan 1, 2006
444.69 B KRW
66.51 B KRW
72.41 B KRW
Jan 1, 2007
531.4 B KRW
80.81 B KRW
53 B KRW
Jan 1, 2008
606.8 B KRW
81.69 B KRW
71.55 B KRW
Jan 1, 2009
691.98 B KRW
74.94 B KRW
50.53 B KRW
Jan 1, 2010
10.98 B KRW
2.73 B KRW
6.98 B KRW
Jan 1, 2011
17.35 B KRW
3.07 B KRW
-14.69 B KRW
Jan 1, 2012
20.18 B KRW
4.15 B KRW
12.48 B KRW
Jan 1, 2013
220.4 B KRW
6.82 B KRW
9.58 B KRW
Jan 1, 2014
532.89 B KRW
9.29 B KRW
21.31 B KRW
Jan 1, 2015
776.63 B KRW
147.07 B KRW
178.52 B KRW
Jan 1, 2016
665.29 B KRW
15.07 B KRW
7.94 B KRW
Jan 1, 2017
652.32 B KRW
13.97 B KRW
30.07 B KRW
Jan 1, 2018
708 B KRW
11 B KRW
18.02 B KRW
Jan 1, 2019
816.62 B KRW
16.15 B KRW
30.74 B KRW

Hanmi Science Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 17, 2026, 2:21 AM
 
REVENUE (T KRW)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B KRW)
NET INCOME (B KRW)
NET INCOME GROWTH (%)
DIV. (KRW)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
20172018201920202021202220232024
0.650.710.820.860.951.051.251.28
-1.958.5315.344.9910.8210.0919.32.85
14.0513.0513.2714.0813.9715.3318.8818.9
91.6492.41108.33120.72132.77160.37235.59242.61
30.0718.0230.7422.642.9469.21115.1259.42
278.8-40.0770.6-26.489061.1766.34-48.38
196.08196.08200196.08196.08196.08200300
-52.742-1.96250
6466666668.6268.4967.9667.72
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Hanmi Science Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hanmi Science Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hanmi Science Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Hanmi Science Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hanmi Science Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Hanmi Science Co stock margins

The Hanmi Science Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hanmi Science Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hanmi Science Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
65.05 %
14.9 %
10.57 %
Jan 1, 2006
68.03 %
14.96 %
16.28 %
Jan 1, 2007
67.15 %
15.21 %
9.97 %
Jan 1, 2008
64.35 %
13.46 %
11.79 %
Jan 1, 2009
60.99 %
10.83 %
7.3 %
Jan 1, 2010
91.01 %
24.87 %
63.56 %
Jan 1, 2011
94.77 %
17.72 %
-84.69 %
Jan 1, 2012
95.71 %
20.55 %
61.84 %
Jan 1, 2013
25.7 %
3.1 %
4.35 %
Jan 1, 2014
12.85 %
1.74 %
4 %
Jan 1, 2015
27.89 %
18.94 %
22.99 %
Jan 1, 2016
12.8 %
2.26 %
1.19 %
Jan 1, 2017
14.05 %
2.14 %
4.61 %
Jan 1, 2018
13.05 %
1.55 %
2.55 %
Jan 1, 2019
13.27 %
1.98 %
3.76 %

Hanmi Science Co Stock Revenue, EBIT, Earnings per Share

The Hanmi Science Co earnings per share therefore indicates how much revenue Hanmi Science Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2005
22,001.22 KRW
3,277.22 KRW
2,324.78 KRW
Jan 1, 2006
24,705.22 KRW
3,694.94 KRW
4,023 KRW
Jan 1, 2007
31,258.59 KRW
4,753.59 KRW
3,117.53 KRW
Jan 1, 2008
35,694.29 KRW
4,805.47 KRW
4,208.88 KRW
Jan 1, 2009
43,248.75 KRW
4,684 KRW
3,157.94 KRW
Jan 1, 2010
203.31 KRW
50.57 KRW
129.22 KRW
Jan 1, 2011
262.82 KRW
46.56 KRW
-222.59 KRW
Jan 1, 2012
305.74 KRW
62.83 KRW
189.08 KRW
Jan 1, 2013
3,194.15 KRW
98.87 KRW
138.81 KRW
Jan 1, 2014
7,722.99 KRW
134.7 KRW
308.87 KRW
Jan 1, 2015
11,948.14 KRW
2,262.6 KRW
2,746.48 KRW
Jan 1, 2016
10,080.08 KRW
228.3 KRW
120.27 KRW
Jan 1, 2017
10,192.56 KRW
218.3 KRW
469.83 KRW
Jan 1, 2018
10,727.2 KRW
166.62 KRW
273.03 KRW
Jan 1, 2019
12,373.02 KRW
244.62 KRW
465.79 KRW

Hanmi Science Co business model & stock analysis

Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future.

Hanmi Science Co SWOT Analysis

Strengths

Hanmi Science Co Ltd has a strong emphasis on research and development, allowing them to continuously innovate and develop new products. This gives them a competitive advantage in the market and enables them to meet the evolving needs of their customers.

The company offers a wide range of products in various therapeutic areas, including pharmaceuticals, vaccines, and medical devices. This diversified portfolio helps them cater to different customer segments and provides stability in their revenue streams.

Hanmi Science Co Ltd has established a strong market presence, both domestically and internationally. Their products are well-regarded, and they have built a reputation for quality and reliability. This helps them attract and retain customers, as well as forge strategic partnerships.

Weaknesses

While Hanmi Science Co Ltd has a robust product portfolio, they still rely heavily on a limited number of key products for a significant portion of their revenues. This makes them vulnerable to market fluctuations and increased competition in those specific product categories.

Compared to some of their larger competitors, Hanmi Science Co Ltd has a relatively small market share. This can limit their bargaining power with suppliers and customers, as well as hinder their ability to invest in new technologies or expand their market reach.

Opportunities

The company has an opportunity to expand its presence in emerging markets, where there is a growing demand for healthcare products. Additionally, exploring international markets further can help Hanmi Science Co Ltd tap into new customer bases, diversify their revenue streams, and reduce dependence on any one market.

Forming strategic partnerships and collaborations with other pharmaceutical companies or research institutions can provide Hanmi Science Co Ltd with access to new technologies, resources, and markets. These alliances can accelerate their product development process and enable them to stay ahead of competitors.

Threats

The pharmaceutical and healthcare industry is highly competitive, with numerous players vying for market share. Hanmi Science Co Ltd faces competition from both domestic and international companies, which can pose a threat to their market position and profitability.

Operating in the pharmaceutical sector involves stringent regulations and compliance requirements. Changes in government policies, pricing regulations, or delays in product approvals can create challenges for Hanmi Science Co Ltd, impacting their ability to bring new products to the market and affecting their revenue streams.

Rapid advancements in technology and the emergence of alternative treatment options can pose a threat to traditional pharmaceutical companies like Hanmi Science Co Ltd. They need to stay updated with the latest trends and invest in research to ensure their products remain relevant and competitive in the market.

Hanmi Science Co Eulerpool Fair Value

Hanmi Science Co historical P/E ratio, EBIT multiple, and P/S ratio

Hanmi Science Co annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Hanmi Science Co shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2005
18 M base_Shares
Jan 1, 2006
18 M base_Shares
Jan 1, 2007
17 M base_Shares
Jan 1, 2008
17 M base_Shares
Jan 1, 2009
16 M base_Shares
Jan 1, 2010
54 M base_Shares
Jan 1, 2011
66 M base_Shares
Jan 1, 2012
66 M base_Shares
Jan 1, 2013
69 M base_Shares
Jan 1, 2014
69 M base_Shares
Jan 1, 2015
65 M base_Shares
Jan 1, 2016
66 M base_Shares
Jan 1, 2017
64 M base_Shares
Jan 1, 2018
66 M base_Shares
Jan 1, 2019
66 M base_Shares

Hanmi Science Co Dividend History

26 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
2024300KRW 50.0%
2023200KRW 2.0%
2022196.08KRW 0.0%
2021196.08KRW 0.0%
2020196.08KRW 2.0%
2019200KRW 2.0%
2018196.08KRW 0.0%
2017196.08KRW 52.7%
2016414.94KRW 17.0%
2015500KRW 64.7%

Hanmi Science Co dividend payout ratio

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2005
11.28 %
Jan 1, 2006
6.52 %
Jan 1, 2007
8.83 %
Jan 1, 2008
6.87 %
Jan 1, 2009
9.61 %
Jan 1, 2010
35.05 %
Jan 1, 2011
35.05 %
Jan 1, 2012
35.05 %
Jan 1, 2013
35.05 %
Jan 1, 2014
35.05 %
Jan 1, 2015
15.11 %
Jan 1, 2016
35.05 %
Jan 1, 2017
37.8 %
Jan 1, 2018
66.35 %
Jan 1, 2019
40.46 %
Price targets and forecasts for Hanmi Science Co are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Hanmi Science Co stock

5/100
6
Environment
7
Social
4
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hanmi Science Co shareholder structure

% Name
16.5985%
Sin (Dong Guk)
Sin (Dong Guk)
9.90982%
Killington Limited
Killington Limited
7.64374%
Im (Ju Hyeon)
Im (Ju Hyeon)
7.02122%
Hanyang Precision Co., Ltd
Hanyang Precision Co., Ltd
6.77529%
Im (Jong Yun)
Im (Jong Yun)
6.19359%
National Pension Service
National Pension Service
5.14478%
Im (Jong Hun)
Im (Jong Hun)
3.41541%
Song (Yeong Suk)
Song (Yeong Suk)
3.10297%
Imseonggi Foundation
Imseonggi Foundation
3.04665%
Gahyeon Cultural Foundation
Gahyeon Cultural Foundation
...

Hanmi Science Co Executives and Management Board

JY

Ms. Ju Hyeon Yim

(49)

Co-President, Director · since 2009

Compensation1.15 B KRW
JY

Mr. Jong Yun Yim

(51)

Co-President, Director · since 2009

Compensation1.13 B KRW
JY

Mr. Jong Hun Yim

(46)

Chief Executive Officer, Director · since 2009

SS

Mr. Seong Jae Shin

(58)

Managing Director

CC

Mr. Chang Ju Choi

(50)

Assistant Managing Director

Hanmi Science Co Supply Chain

Frequently asked questions about Hanmi Science Co

The business model of Hanmi Science Co Ltd., a South Korean company, revolves around its expertise in the field of biotechnology. Hanmi Science focuses on the development, manufacturing, and distribution of innovative pharmaceutical products. The company is committed to researching and creating cutting-edge drugs and therapies to address various medical conditions and improve patient outcomes. With a strong emphasis on research and development, Hanmi Science aims to enhance global healthcare by delivering novel treatment options to customers worldwide.

All fundamentals and in-depth analysis of Hanmi Science Co

Our stock analysis for Hanmi Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanmi Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.